Maryam Zarghami Dehaghani

Maryam Zarghami Dehaghani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maryam Zarghami Dehaghani has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive stochastic modeling of mechanically alloyed particle size and shape

    by Anand Prakash Dwivedi, Emad Iranmanesh, Katerina Sofokleous, Vassilis Drakonakis, Amin Hamed Mashhadzadeh, Maryam Zarghami Dehaghani, Boris Golman, Christos Spitas, Charalabos C. Doumanidis

    Ball milling bimetallic materials creates tailored particles—size, shape, and nanostructure define performance for catalysis, energy, and beyond.


  • Microstructural evolution and crystalline behavior in silicon carbide nano-powder during selective laser melting: A molecular dynamics simulation

    by Amin Hamed Mashhadzadeh, Maryam Zarghami Dehaghani, Haris Doumanidis, Boris Golman, Konstantinos V. Kostas, Christos Spitas


  • Open Access

    Theoretical Encapsulation of Fluorouracil (5-FU) Anti-Cancer Chemotherapy Drug into Carbon Nanotubes (CNT) and Boron Nitride Nanotubes (BNNT)

    by Maryam Zarghami Dehaghani, Farrokh Yousefi, S. Mohammad Sajadi, Muhammad Tajammal Munir, Otman Abida, Sajjad Habibzadeh, Amin Hamed Mashhadzadeh, Navid Rabiee, Ebrahim Mostafavi, Mohammad Reza Saeb

    Introduction: Chemotherapy with anti-cancer drugs is considered the most common approach for killing cancer cells in the human body. However, some barriers such as toxicity and side effects would limit its usage. In this regard, nano-based drug delivery systems have emerged as cost-effective and efficient for sustained and targeted drug delivery. Nanotubes such as carbon nanotubes (CNT) and boron nitride nanotubes (BNNT) are promising nanocarriers that provide the cargo with a large inner volume for encapsulation. However, understanding the insertion process of the anti-cancer drugs into the nanotubes and demonstrating drug-nanotube interactions starts with theoretical analysis. Methods: First, interactions parameters of the atoms of 5-FU were quantified from the DREIDING force field. Second, the storage capacity of BNNT (8,8) was simulated to count the number of drugs 5-FU encapsulated inside the cavity of the nanotubes. In terms of the encapsulation process of the one drug 5-FU into nanotubes, it was clarified that the drug 5-FU was more rapidly adsorbed into the cavity of the BNNT compared with the CNT due to the higher van der Waals (vdW) interaction energy between the drug and the BNNT. Results: The obtained values of free energy confirmed that the encapsulation process of the drug inside the CNT and BNNT occurred spontaneously with the free energies of −14 and −25 kcal·mol−1, respectively. Discussion: However, the lower value of the free energy in the system containing the BNNT unraveled more stability of the encapsulated drug inside the cavity of the BNNT comparing the system having CNT. The encapsulation of Fluorouracil (5-FU) anti-cancer chemotherapy drug (commercial name: Adrucil®) into CNT (8,8) and BNNT (8,8) with the length of 20 Å in an aqueous solution was discussed herein applying molecular dynamics (MD) simulation.